Current clinical trials of BAY 43-9006, Part 1

ONCOLOGY

Volumn 19, Issue 4, 2005, Pages 499-502

  Wright, John J ^a   Zerivitz, Ken ^b   Gravell, Amy ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Technical Resources International Inc   (United States)

^c EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINOGELDANOMYCIN; ANASTROZOLE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; ERLOTINIB; GEMCITABINE; IMATINIB; IRINOTECAN; KETOCONAZOLE; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE; RAF PROTEIN; SORAFENIB; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INHIBITION; DRY SKIN; DYSPNEA; ENZYME ACTIVITY; ERYTHEMA; FATIGUE; FEVER; FLATULENCE; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GLIOMA; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERSENSITIVITY; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MESOTHELIOMA; MYALGIA; NAUSEA AND VOMITING; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PAIN; PANCREAS CARCINOMA; PANCREATITIS; PROSTATE CANCER; PRURITUS; RASH; SARCOMA; SENSORY NEUROPATHY; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; THYROID CARCINOMA; TUMOR GROWTH; WEIGHT REDUCTION; NEOPLASM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; BENZENESULFONATES; CLINICAL TRIALS; HUMANS; NEOPLASMS; PYRIDINES;

EID: 35748951943     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Carter C, Wessler C, Gellert J, et al (eds): Investigator's Brochure, version 5. West Haven, Conn, Bayer Pharmaceuticals Corp, 2004.
2. Campbell SL, Khosravi-Far R, Rossman KL, et al: Increasing complexity of Ras signaling. Oncogene 17:1395-1413, 1998.
3. Chong H, Vikis HG, Guan KL: Mechanisms of regulating the Raf kinase family. Cell Signal 15:463-469, 2003.
4. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002.
5. Mercer KE, Pritchard CA: Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653:25-40, 2003.
6. Pollock PM, Meltzer PS: A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2:5-7, 2002.
7. Singer G, Oldt R 3rd, Cohen Y, et al: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484-486, 2003.
8. Tannapfel A, Sommerer F, Benicke M, et al: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52:706-712, 2003.
9. Cohen Y, Xing M, Mambo E, et al: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627, 2003.
10. Ferrara N: VEGF and the quest for tumor angiogenesis factors. Nat Rev Cancer 2:795-803, 2002.
11. Bergers G, Song S, Meyer-Morse N, et al: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1205, 2003.
12. Apperley JF, Gardembas M, Melo JV, et al: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481-487, 2002.
13. Sawyers CL: Finding the next Gleevec: FLT-3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 1:413-415, 2002.
14. Heinrich MC, Blanke CD, Druker BJ, et al: Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692-1703, 2002.